You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrabectedin
Accession NumberDB05109
TypeSmall Molecule
GroupsApproved, Investigational
Description

Trabectedin, also referred as ET-743 during its development, is a marine derived antitumoral agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas. The European Commission and the U.S. Food and Drug Administration (FDA) have granted orphan drug status to trabectedin for soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.

Structure
Thumb
Synonyms
Ecteinascidin 743
External Identifiers
  • ET-743
  • NSC 684766
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Yondelisinjection, powder, lyophilized, for solution.05 mg/mLintravenousJanssen Products, LP2015-10-23Not applicableUs
Yondelispowder for solution1 mgintravenousJanssen Inc2010-08-05Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIID0YZQ2TCP
CAS number114899-77-3
WeightAverage: 761.837
Monoisotopic: 761.261829923
Chemical FormulaC39H43N3O11S
InChI KeyInChIKey=PKVRCIRHQMSYJX-AIFWHQITSA-N
InChI
InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
IUPAC Name
(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxo-3',4'-dihydro-2'H-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1³,¹¹.0²,¹³.0⁴,⁹.0¹⁵,²³.0¹⁶,²⁰]triacontane-26,1'-isoquinoline]-4,6,8,15,20,22-hexaen-22-yl acetate
SMILES
[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[[email protected]](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[[email protected]]2N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzazocines. These are organic compounds containing the benzazocine ring system, which consists of a benzene ring bound to an azocine ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzazocines
Direct ParentBenzazocines
Alternative Parents
Substituents
  • Benzazocine
  • Tetrahydroisoquinoline
  • Methoxyphenol
  • Alpha-amino acid or derivatives
  • Benzodioxole
  • Anisole
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Alkyl aryl ether
  • Piperazine
  • 1,4-diazinane
  • Acetate salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Polyol
  • Lactone
  • Hemiaminal
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Dialkylthioether
  • Thioether
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Alkanolamine
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors.
PharmacodynamicsTwo of the rings in the drug's structure allows it to covalently bind to the minor groove of DNA. The third ring protrudes from the DNA which lets it interact with nearby nuclear proteins. This has the additive effect of blocking cell division at the G2 phase.
Mechanism of actionTrabectedin interacts with the minor groove of DNA and alkylates guanine at the N2 position, which bends towards the major groove. In this manner, it is thought that the drug affects various transcription factors involved in cell proliferation, particularly via the transcription-coupled nucleotide excision repair system. Trabectedin blocks the cell cycle at the G2 phase, while cells at the G1 phase are most sensitive to the drug. It also inhibits overexpression of the multidrug resistance-1 gene (MDR-1) coding for the P-glycoprotein that is a major factor responsible for cells developing resistance to cancer drugs. The agent is also thought to interfere with the nucleotide excision repair pathways of cancer cells, suggesting that it could be effective in the treatment of many cancer types including melanoma and sarcoma, as well as lung, breast, ovarian, endometrial and prostate cancers; clinical evaluations are underway in these indications.
Related Articles
AbsorptionAdministered intravenously.
Volume of distributionNot Available
Protein binding94 to 98%
Metabolism
SubstrateEnzymesProduct
Trabectedin
Not Available
Trabectedin metabolite M8aDetails
Trabectedin
Not Available
Trabectedin metabolite M8b (ET-729)Details
Trabectedin
Not Available
Trabectedin metabolite M9Details
Trabectedin
Not Available
Trabectedin metabolite 16cDetails
Trabectedin
Not Available
Trabectedin metabolite M16eDetails
Trabectedin metabolite M8a
Not Available
Trabectedin metabolite M16eDetails
Route of eliminationNot Available
Half life33-50 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5216
Blood Brain Barrier-0.9238
Caco-2 permeable-0.6788
P-glycoprotein substrateSubstrate0.8988
P-glycoprotein inhibitor INon-inhibitor0.6957
P-glycoprotein inhibitor IINon-inhibitor0.74
Renal organic cation transporterNon-inhibitor0.8321
CYP450 2C9 substrateNon-substrate0.8211
CYP450 2D6 substrateNon-substrate0.7689
CYP450 3A4 substrateSubstrate0.6512
CYP450 1A2 substrateNon-inhibitor0.804
CYP450 2C9 inhibitorNon-inhibitor0.5287
CYP450 2D6 inhibitorNon-inhibitor0.6514
CYP450 2C19 inhibitorNon-inhibitor0.5436
CYP450 3A4 inhibitorInhibitor0.8832
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6677
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.8734
BiodegradationNot ready biodegradable0.9782
Rat acute toxicity2.6136 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9942
hERG inhibition (predictor II)Inhibitor0.5329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous.05 mg/mL
Powder for solutionintravenous1 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2373794 No2005-10-112020-05-15Canada
CA2428160 No2009-10-132021-11-06Canada
US8895557 No2008-01-072028-01-07Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.328 mg/mLALOGPS
logP2.04ALOGPS
logP3.99ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)9.27ChemAxon
pKa (Strongest Basic)7.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area168.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity196.92 m3·mol-1ChemAxon
Polarizability77.72 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Elias J. Corey, David Gin, “Process for producing ecteinascidin compounds.” U.S. Patent US5721362, issued December, 1995.

US5721362
General References
  1. Tavecchio M, Natoli C, Ubezio P, Erba E, D'Incalci M: Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif. 2007 Dec;40(6):885-904. [PubMed:18021177 ]
  2. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME: A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17;97(12):1618-24. Epub 2007 Nov 13. [PubMed:18000504 ]
  3. Carter NJ, Keam SJ: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67(15):2257-76. [PubMed:17927287 ]
  4. Authors unspecified: Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D. 2006;7(5):317-28. [PubMed:16922593 ]
  5. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
External Links
ATC CodesL01CX01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (824 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AprepitantThe serum concentration of Trabectedin can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Trabectedin can be increased when it is combined with Atazanavir.
AtorvastatinAtorvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
BexaroteneThe serum concentration of Trabectedin can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Trabectedin can be increased when it is combined with Boceprevir.
BosentanThe serum concentration of Trabectedin can be decreased when it is combined with Bosentan.
CarbamazepineThe serum concentration of Trabectedin can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Trabectedin can be increased when it is combined with Ceritinib.
ClarithromycinThe serum concentration of Trabectedin can be increased when it is combined with Clarithromycin.
ClozapineThe risk or severity of adverse effects can be increased when Trabectedin is combined with Clozapine.
CobicistatThe serum concentration of Trabectedin can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Trabectedin can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Trabectedin can be increased when it is combined with Crizotinib.
DabrafenibThe serum concentration of Trabectedin can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Trabectedin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Trabectedin can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Trabectedin can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Trabectedin can be increased when it is combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Trabectedin.
DiltiazemThe serum concentration of Trabectedin can be increased when it is combined with Diltiazem.
DronedaroneThe serum concentration of Trabectedin can be increased when it is combined with Dronedarone.
EnzalutamideThe serum concentration of Trabectedin can be decreased when it is combined with Enzalutamide.
ErythromycinThe serum concentration of Trabectedin can be increased when it is combined with Erythromycin.
EthanolEthanol may increase the hepatotoxic activities of Trabectedin.
FluconazoleThe serum concentration of Trabectedin can be increased when it is combined with Fluconazole.
FluvastatinFluvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
FosamprenavirThe serum concentration of Trabectedin can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Trabectedin can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Trabectedin can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Trabectedin can be increased when it is combined with Fusidic Acid.
IdelalisibThe serum concentration of Trabectedin can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Trabectedin can be increased when it is combined with Imatinib.
IndinavirThe serum concentration of Trabectedin can be increased when it is combined with Indinavir.
IsavuconazoniumThe serum concentration of Trabectedin can be increased when it is combined with Isavuconazonium.
ItraconazoleThe serum concentration of Trabectedin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Trabectedin can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Trabectedin can be increased when it is combined with Ketoconazole.
LeflunomideThe risk or severity of adverse effects can be increased when Trabectedin is combined with Leflunomide.
LovastatinLovastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
LuliconazoleThe serum concentration of Trabectedin can be increased when it is combined with Luliconazole.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Trabectedin.
MifepristoneThe serum concentration of Trabectedin can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Trabectedin can be decreased when it is combined with Mitotane.
NatalizumabThe risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.
NefazodoneThe serum concentration of Trabectedin can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Trabectedin can be increased when it is combined with Nelfinavir.
NilotinibThe serum concentration of Trabectedin can be increased when it is combined with Nilotinib.
PalbociclibThe serum concentration of Trabectedin can be increased when it is combined with Palbociclib.
PhenobarbitalThe serum concentration of Trabectedin can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Trabectedin can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trabectedin.
PitavastatinPitavastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
PosaconazoleThe serum concentration of Trabectedin can be increased when it is combined with Posaconazole.
PravastatinPravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
PrimidoneThe serum concentration of Trabectedin can be decreased when it is combined with Primidone.
RanolazineThe serum concentration of Trabectedin can be increased when it is combined with Ranolazine.
RifabutinThe serum concentration of Trabectedin can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Trabectedin can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Trabectedin can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Trabectedin can be increased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Trabectedin.
RosuvastatinRosuvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
SaquinavirThe serum concentration of Trabectedin can be increased when it is combined with Saquinavir.
SiltuximabThe serum concentration of Trabectedin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Trabectedin can be increased when it is combined with Simeprevir.
SimvastatinSimvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trabectedin.
St. John's WortThe serum concentration of Trabectedin can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Trabectedin can be increased when it is combined with Stiripentol.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Trabectedin.
TelaprevirThe serum concentration of Trabectedin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Trabectedin can be increased when it is combined with Telithromycin.
TesmilifeneThe serum concentration of Trabectedin can be decreased when it is combined with Tesmilifene.
TocilizumabThe serum concentration of Trabectedin can be decreased when it is combined with Tocilizumab.
TofacitinibTrabectedin may increase the immunosuppressive activities of Tofacitinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Trabectedin.
VerapamilThe serum concentration of Trabectedin can be increased when it is combined with Verapamil.
VoriconazoleThe serum concentration of Trabectedin can be increased when it is combined with Voriconazole.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. D'Incalci M, Galmarini CM: A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010 Aug;9(8):2157-63. doi: 10.1158/1535-7163.MCT-10-0263. Epub 2010 Jul 20. [PubMed:20647340 ]
  3. Marco E, David-Cordonnier MH, Bailly C, Cuevas C, Gago F: Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. J Med Chem. 2006 Nov 16;49(23):6925-9. [PubMed:17154523 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on August 24, 2016 01:53